STAT News reports that Partners Healthcare CEO Dr. David Torchiana was among the health care executive who met with President-elect Donald Trump Wenesday. Torchiana has been among those arguing that repeal of the law could disrupt millions of families who have relied upon it for insurance coverage. “De-insuring 20 million people, many of whom were probably Trump … Continue reading From today’s Boston Globe: Partners and Trump, health costs and another expensive drug
In her "Gut Check" column, STAT's Sharon Begley notes that a NEJM report from Boston University's Framingham Heart Study claims that "The percent of people developing dementia each year is falling significantly... raising hope that some cases can be prevented and, possibly, that the worst forecasts of a “looming dementia crisis in the United States are overblown" … Continue reading #STATnews asks: Are #Alzheimer’s numbers inflated?
The New York Times reports: As complaints grow about exorbitant drug prices, pharmaceutical companies are coming under pressure to disclose the development costs and profits of those medicines and the rationale for charging what they do. So-called pharmaceutical cost transparency bills have been introduced in at least six state legislatures in the last year, aiming … Continue reading Massachusetts thread in NYTimes story on drug price rekoning
Robert Weisman of the Globe reports today: California scientist Paul M. Quinton learned that he has cystic fibrosis at age 19 and has spent his long career in his lab working on ways to cure it. He is, in short, not the kind of person you’d expect to be fighting with Vertex Pharmaceuticals Inc., the … Continue reading Why won’t the Cystic Fibrosis Foundation comment on the high price of the new Vertex drug?
The scene at the FDA hearing was familiar. All the advisory committees have seen it play out again and again. Yesterday, it was the Pulmonary-Allergy Drug committee: The pharma doc with the convincing statement. The weeping patients. The drug likely to cost a couple thousand a month offering a slim benefit over an existing drugs. … Continue reading Should the FDA approve Vertex’s new cystic fibrosis drug?
From ProPublica on me-too meds. Yale's Dr. Joseph Ross gets a quote in this story. , Vox offers a summary of his NEJM piece on digital marketing to docs. More here on his work into the accuracy of clinical trial registries. Here's the NEJM abstract: Pharmaceutical marketing can lead to overdiagnosis, overtreatment, and overuse of medications. Digital … Continue reading Yale’s Dr. Ross and the promotion of me-too meds
And some comments from the Knight Science Journalism Tracker: A new cystic fibrosis drug--the first to be developed based on understanding of the genetics of the illness--is an orphan drug that can help only about 4 percent of patients with cystic fibrosis. Its financial toxicity is such that it can destroy the finances of those … Continue reading A closer look at the downside of the Vertex – Cystic Fibrosis Foundation deal